Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ascendis Pharma ADR
(NQ:
ASND
)
139.68
+0.29 (+0.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ascendis Pharma ADR
< Previous
1
2
3
4
5
6
Next >
Recap: Ascendis Pharma Q3 Earnings
November 07, 2023
Via
Benzinga
Preview: Ascendis Pharma's Earnings
November 06, 2023
Via
Benzinga
The Latest Analyst Ratings for Ascendis Pharma
October 09, 2023
Via
Benzinga
Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty
September 28, 2023
Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in
Via
Benzinga
The Latest Analyst Ratings for Ascendis Pharma
September 07, 2023
Via
Benzinga
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
September 05, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Earnings Preview For Ascendis Pharma
September 04, 2023
Via
Benzinga
Analyst Expectations for Ascendis Pharma's Future
July 24, 2023
Via
Benzinga
Where Ascendis Pharma Stands With Analysts
June 20, 2023
Via
Benzinga
The Latest Analyst Ratings for Ascendis Pharma
June 01, 2023
Via
Benzinga
FDA Rejects Ascendis Pharma's TransCon PTH For Hypoparathyroidism
May 01, 2023
The FDA issued a complete response letter (CRL) for Ascendis Pharma A/S's
Via
Benzinga
Earnings Scheduled For September 5, 2023
September 05, 2023
Companies Reporting Before The Bell • Procaps Gr (NASDAQ:PROC) is likely to report earnings for its second quarter.
Via
Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm
June 30, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm
June 25, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Why Shares of Ascendis Pharma Are Climbing Monday
May 01, 2023
A critical response letter from the FDA means hope remains for the company's hyperthyroidism therapy candidate.
Via
The Motley Fool
Why Ascendis Pharma Stock Is Crashing This Week
April 06, 2023
The FDA put a roadblock in the path to market for Ascendis' hypoparathyroidism drug.
Via
The Motley Fool
NASDAQ: ASND Investor Alert: Investigation over Potential Wrongdoing at Ascendis Pharma A/S
June 20, 2023
San Diego, CA -- (SBWIRE) -- 06/20/2023 -- Certain directors of Ascendis Pharma A/S are under investigation over potential breaches of fiduciary duties by certain directors.
Via
SBWire
Bragar Eagel & Squire, P.C. Is Investigating C3.ai, Ascendis, Alvotech, and Shift4 and Encourages Investors to Contact the Firm
June 19, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
May 01, 2023
Via
Benzinga
US Stocks Rise; Norwegian Cruise Line Posts Q1 Results
May 01, 2023
U.S. stocks traded higher this morning, ahead of the Federal Reserve’s monetary policy meeting. Following the market opening Monday, the Dow traded up 0.15% to 34,147.97, while the NASDAQ inched up...
Via
Benzinga
IVERIC bio, Ascendis Pharma And Other Big Stocks Moving Higher In Monday's Pre-Market Session
May 01, 2023
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Apollomics, Inc. (NASDAQ: APLM) surged 58.4% to $7.35 in pre-market trading...
Via
Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Fox, Ascendis, and Shift4 and Encourages Investors to Contact the Firm
April 28, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Hedge Funds Fall Short: Underperforming Low-Cost S&P 500 ETF By 6% In 2023. Here's Why.
April 20, 2023
So far, 2023 has not started well for the hedge fund sector, as a common SPDR S&P 500 Trust ETF (ARCA: SPY) fared much better than the Global X Guru Index ETF (ARCA: GURU), a fund that invests in the...
Via
Benzinga
NASDAQ: ASND Shareholder Notice: Investigation over Possible Securities Laws Violations by Ascendis Pharma A/S
April 17, 2023
San Diego, CA -- (SBWIRE) -- 04/17/2023 -- Ascendis Pharma A/S is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation - ASND
April 14, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
April 12, 2023
Via
Benzinga
ASCENDIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ascendis Pharma A/S on Behalf of Ascendis Stockholders and Encourages Investors to Contact the Firm
April 07, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2023
April 05, 2023
Via
Benzinga
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ascendis Pharma A/S (ASND) Investigation
April 04, 2023
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023
April 04, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.